The Abramson Cancer Center of the University of Pennsylvania
Last Modified: February 3, 2004
The Colon Sibling Pair Study sponsored by The National Cancer Genetics Network has been developed to help researchers better understand what causes colon or rectal cancer. For this project, researchers are interested in studying brothers and sisters who have had colon or rectal cancer. Many research studies need more participants than any one cancer research center can enroll. Therefore, the national network is made up of eight major sites, each selected by the National Cancer Institute for the excellence of their work in cancer genetics.
There are no costs associated with participation.
You will be invited to be in this study if:
You and one of your siblings have had colon or rectal cancer.
As part of this study, your tumor will be studied for markers of hereditary risk. If testing finds that you have genetic risk to develop cancer, this information could be extremely useful for you and your family. Tailored follow-up recommendations can be made to help prevent cancer from developing. In addition, the information learned may help future generations.
You may have some mild pain when your blood is drawn.
Discussion about inherited risk for developing colon or rectal cancer may cause concern or anxiety. If you or your family has concerns about your genetic status or want more information about your inherited risk for developing cancer, study personnel can refer you to experts for genetic counseling. There could be an additional cost to you for this service.
Every effort will be made to protect your confidentiality. All your information obtained for this study will be kept private. Study staff takes great care to make sure that your study information stays private.
You can find out if this study is right for you by contacting Rhonda Kitlas Gillette, Research Coordinator for the Colon Sibling Pair Study, at the Abramson Cancer Center of the University of Pennsylvania, toll free at 1-888-666-6002 or via email at firstname.lastname@example.org.
Nov 2, 2010 - Most recent oncology randomized controlled trials evaluate drugs that are available "off-protocol therapy" in the United States, and this can adversely impact trial enrollment, according to a study published online Oct. 25 in the Journal of Clinical Oncology.
Nov 2, 2010
Nov 30, 2010
Jun 24, 2010